On May 16, 2019 Flatiron Health reported 16 abstracts accepted for presentation at the 2019 American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which will be held May 31 – June 4 in Chicago (Press release, Flatiron Health, MAY 16, 2019, View Source [SID1234536448]). The research, spanning multiple tumor types and areas of study, utilized Flatiron’s high-quality, real-world oncology datasets.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The research to be presented includes collaborations between Flatiron and the U.S. Food and Drug Administration, National Cancer Institute, Amgen, Eli Lilly and Company, Pfizer, Roche/Genentech and Foundation Medicine.
The presentation schedule and links to abstracts can be found below. Learn more about our abstracts by clicking on each link or see our recent blog post for more information.
Plenary Session
Affordable Care Act (ACA) Medicaid Expansion Impact on Racial Disparities in Time to Cancer Treatment
Presenting Author: Amy Davidoff, PhD (Yale School of Public Health)
Date/Time: June 2 — 1:45 – 2:00pm
Abstract: #LBA1
Location: Hall B1
Track: Special Sessions
Poster Discussion
Genomic Characterization of Lung Tumors and Metastatic Sites in Advanced NSCLC
First Author: Melinda Willard (Eli Lilly and Company)
Date/Time: June 2 — 4:30 – 6:00pm
Abstract: #2014
Poster: #203
Location: S404
Track: Central Nervous System Tumors
Poster Sessions (Location: Hall A)
Organ Dysfunction and Clinical Outcomes in Patients Treated with Immune Checkpoint Inhibitors
First Author: Qi Li, PhD (U.S. Food and Drug Administration)
Date/Time: June 1 — 8:00 – 11:00am
Abstract: #2569
Poster: #213
Track: Developmental Immunotherapy and Tumor Immunobiology
Tumor Mutational Burden and PD-L1 Expression as Predictors of Response to Immunotherapy in NSCLC
First Author: Emily Castellanos, MD, MPH (Flatiron Health)
Date/Time: June 1 — 8:00 – 11:00am
Abstract: #2630
Poster: #274
Track: Developmental Immunotherapy and Tumor Immunobiology
Impact of Oncology Care Model Reporting Requirements on Quality of Care
First Author: Emily Castellanos, MD, MPH (Flatiron Health)
Date/Time: June 1 — 1:15 – 4:15pm
Abstract: #6620
Poster: #311
Track: Health Services Research, Clinical Informatics, and Quality of Care
Using Real-World Cohorts to Assess the Generalizability and Relevance of Randomized Clinical Trials
First Author: Caroline Bennette, MPH, PhD (Flatiron Health)
Date/Time: June 1 — 1:15 – 4:15pm
Abstract: #6540
Poster: #231
Track: Health Services Research, Clinical Informatics, and Quality of Care
Clinical Characteristics, Treatment Patterns, and Overall Survival in Advanced NSCLC Patients With and Without Brain Metastases
First Author: Emily Nash Smyth, PharmD (Eli Lilly and Company)
Date/Time: June 2 — 8:00 – 11:00am
Abstract: #2035
Poster: #224
Track: Central Nervous System Tumors
Identification and Use of Treatment Options in Patients with Advanced Non-Small Cell Lung Cancer After Comprehensive Genomic Profiling: A Real-World Study
First Author: Celine Mascaux, MD, PhD (Aix-Marseille University)
Date/Time: June 2 — 8:00 – 11:00am
Abstract: #9076
Poster: #399
Track: Lung Cancer—Non-Small Cell Metastatic
Real-World Evidence of Male Breast Cancer Patients Treated with Palbociclib in Combination with Endocrine Therapy
First Author: Cynthia Huang Bartlett, MD (Pfizer)
Date/Time: June 2 — 8:00 – 11:00am
Abstract: #1055
Poster: #136
Track: Breast Cancer—Metastatic
Real-World Practice Patterns and Impact of PD-L1 Expression Testing in Patients with Advanced Non-Small Cell Lung Cancer
First Author: Michael Leapman, MD (Yale School of Medicine)
Date/Time: June 2 — 8:00 – 11:00am
Abstract: #9059
Poster: #382
Track: Lung Cancer—Non-Small Cell Metastatic
Real-World Utilization of EGFR TKI Therapies and Treatment Outcomes in Patients with Advanced EGFR-Sensitizing Mutation-Positive NSCLC
First Author: Gregory J. Riely, MD, PhD (Memorial Sloan Kettering Cancer Center)
Memorial Sloan Kettering Cancer Center
Date/Time: June 2 — 8:00 – 11:00am
Abstract: #9062
Poster: #385
Track: Lung Cancer—Non-Small Cell Metastatic
Time-to-Treatment Discontinuation and Real-World Progression-Free Survival as Endpoints for Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive NSCLC Patients
First Author: Robert Charles Doebele, MD, PhD (University of Colorado)
Date/Time: June 2 — 8:00 – 11:00am
Abstract: #9070
Poster: #393
Track: Lung Cancer—Non-Small Cell Metastatic
Validation of Broad Panel Clinical Sequencing-Based Genomic Risk Stratification in Patients with Advanced Lung Adenocarcinomas
First Author: Sam Whipple, MSPH (Genentech)
Date/Time: June 2 — 8:00 – 11:00am
Abstract #9113
Poster #436
Track: Lung Cancer—Non-Small Cell Metastatic
Chromosome 1 Abnormalities and Clinical Outcomes in Multiple Myeloma in the Era of Novel Agents
First Author: Smith Giri, MBBS (Yale School of Medicine)
Date/Time: June 3 — 8:00 – 11:00am
Abstract: #8044
Poster: #370
Track: Hematologic Malignancies—Plasma Cell Dyscrasia
Burden of Thrombocytopenia in Adult Cancer Patients Receiving Chemotherapy
First Author: Gerald Soff, MD (Memorial Sloan Kettering Cancer Center)
Date/Time: June 3 — 1:15 – 4:15pm
Abstract: #1555
Poster: #49
Track: Cancer Prevention, Hereditary Genetics, and Epidemiology
Treatment Characteristics of Patients with Locally Advanced or Metastatic Urothelial Cancer (mUC) Receiving Checkpoint Inhibitor Monotherapy in a US Clinical Practice
First Author: Alicia Morgans, MD, MPH (Northwestern University)
Date/Time: June 3 — 1:15 – 4:15pm
Abstract: #4526
Poster: #352
Track: Genitourinary (Nonprostate) Cancer
About Flatiron Health
Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. Our platform enables cancer researchers and care providers to learn from the experience of every patient. Currently, Flatiron partners with over 280 community cancer practices, seven major academic research centers and over 15 of the top therapeutic oncology companies. For more information, please visit View Source